Literature DB >> 15561709

A relaxed discrimination of 2'-O-methyl-GTP relative to GTP between de novo and Elongative RNA synthesis by the hepatitis C RNA-dependent RNA polymerase NS5B.

Hélène Dutartre1, Joëlle Boretto, Jean Claude Guillemot, Bruno Canard.   

Abstract

Several nucleotide analogues have been described as inhibitors of NS5B, the essential viral RNA-dependent RNA polymerase of hepatitis C virus. However, their precise mode of action remains poorly defined at the molecular level, much like the different steps of de novo initiation of viral RNA synthesis. Here, we show that before elongation, de novo RNA synthesis is made of at least two distinct kinetic phases, the creation of the first phosphodiester bond being the most efficient nucleotide incorporation event. We have studied 2'-O-methyl-GTP as an inhibitor of NS5B-directed RNA synthesis. As a nucleotide competitor of GTP in RNA synthesis, 2'-O-methyl-GTP is able to act as a chain terminator and inhibit RNA synthesis. Relative to GTP, we find that this analogue is strongly discriminated against at the initiation step ( approximately 150-fold) compared with approximately 2-fold at the elongation step. Interestingly, discrimination of the 2'-O-methyl-GTP at initiation is suppressed in a variant NS5B deleted in a subdomain critical for initiation (the "flap," encompassing amino acids 443-454), but not in P495L NS5B, which shows a selective alteration of transition from initiation to elongation. Our results demonstrate that the conformational change occurring between initiation and elongation is dependent on the allosteric GTP-binding site and relaxes nucleotide selectivity. RNA elongation may represent the most probable target of 2'-modified nucleotide analogues, because it is more permissive to inhibition than initiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561709     DOI: 10.1074/jbc.M410191200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Identification and functional characterization of the nascent RNA contacting residues of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Robert Vaughan; Baochang Fan; Jin-Sam You; C Cheng Kao
Journal:  RNA       Date:  2012-06-26       Impact factor: 4.942

2.  General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues.

Authors:  Hélène Dutartre; Cécile Bussetta; Joëlle Boretto; Bruno Canard
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

3.  Identification of a structural element of the hepatitis C virus minus strand RNA involved in the initiation of RNA synthesis.

Authors:  Kathleen Mahias; Neveen Ahmed-El-Sayed; Cyril Masante; Juliette Bitard; Cathy Staedel; Fabien Darfeuille; Michel Ventura; Thérèse Astier-Gin
Journal:  Nucleic Acids Res       Date:  2010-03-01       Impact factor: 16.971

4.  A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase.

Authors:  Sreedhar Chinnaswamy; Ian Yarbrough; Satheesh Palaninathan; C T Ranjith Kumar; Vinodhini Vijayaraghavan; Borries Demeler; Stanley M Lemon; James C Sacchettini; C Cheng Kao
Journal:  J Biol Chem       Date:  2008-04-28       Impact factor: 5.157

5.  Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site.

Authors:  Dinesh Manvar; Kamlendra Singh; Virendra N Pandey
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

6.  Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis.

Authors:  Déborah Harrus; Neveen Ahmed-El-Sayed; Philip C Simister; Steve Miller; Martine Triconnet; Curt H Hagedorn; Kathleen Mahias; Félix A Rey; Thérèse Astier-Gin; Stéphane Bressanelli
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

7.  Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.

Authors:  Julie A Heck; Angela M I Lam; Nirupama Narayanan; David N Frick
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

8.  Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells.

Authors:  Pantxika Bellecave; Christian Cazenave; Julie Rumi; Cathy Staedel; Ophélie Cosnefroy; Marie-Line Andreola; Michel Ventura; Laura Tarrago-Litvak; Thérèse Astier-Gin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

9.  1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.

Authors:  Origène Nyanguile; Frederik Pauwels; Walter Van den Broeck; Carlo W Boutton; Ludo Quirynen; Tania Ivens; Liesbet van der Helm; Geneviève Vandercruyssen; Wendy Mostmans; Frédéric Delouvroy; Pascale Dehertogh; Maxwell D Cummings; Jean-Francois Bonfanti; Kenneth A Simmen; Pierre Raboisson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

10.  Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.

Authors:  Jérôme Deval; Megan H Powdrill; Claudia M D'Abramo; Luciano Cellai; Matthias Götte
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.